AstraZeneca Plc said that its antibody-drug conjugate (ADC) datopotamab deruxtecan generated positive data from patients in a Phase 3 lung cancer trial, but that some Grade 5 events were observed in the study. A spokesperson for AstraZeneca said on 11 July that some Grade 5 interstitial lung disease events were observed which are being investigated. Overall the safety profile of the drug was consistent with previous studies, she added.
